Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $210.1 million.

  • Tango Therapeutics' Liabilities and Shareholders Equity fell 4037.26% to $210.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 3266.01%. This contributed to the annual value of $316.5 million for FY2024, which is 2138.15% down from last year.
  • Per Tango Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $210.1 million for Q3 2025, which was down 4037.26% from $237.9 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $530.1 million for Q3 2021, and its period low was $167.5 million during Q2 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $402.6 million (2023), whereas its average is $367.3 million.
  • As far as peak fluctuations go, Tango Therapeutics' Liabilities and Shareholders Equity skyrocketed by 21483.87% in 2021, and later tumbled by 4037.26% in 2025.
  • Quarter analysis of 5 years shows Tango Therapeutics' Liabilities and Shareholders Equity stood at $500.2 million in 2021, then fell by 12.73% to $436.5 million in 2022, then dropped by 7.77% to $402.6 million in 2023, then fell by 21.38% to $316.5 million in 2024, then crashed by 33.6% to $210.1 million in 2025.
  • Its Liabilities and Shareholders Equity was $210.1 million in Q3 2025, compared to $237.9 million in Q2 2025 and $274.3 million in Q1 2025.